Research programme: antifungals - Micrologix BiotechAlternative Names: Antifungals research programme: Micrologix Biotech; Polyene macrolide research programme - Micrologix Biotech; Research programme: polyene macrolides - Micrologix Biotech
Latest Information Update: 17 Aug 2004
At a glance
- Originator MIGENIX
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 17 Aug 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 17 Aug 2004 Discontinued - Preclinical for Mycoses in Canada (unspecified route)
- 28 May 2002 Preclinical trials in Mycoses in USA (unspecified route)